Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $28.2 million.

  • Arrowhead Pharmaceuticals' Income from Continuing Operations rose 11611.82% to $28.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $233.5 million, marking a year-over-year increase of 13595.3%. This contributed to the annual value of $30.1 million for FY2025, which is 10493.92% up from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Income from Continuing Operations stood at $28.2 million for Q4 2025, which was up 11611.82% from $16.1 million recorded in Q3 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Income from Continuing Operations peaked at $367.8 million during Q1 2025, and registered a low of -$178.7 million during Q2 2025.
  • Moreover, its 5-year median value for Income from Continuing Operations was -$67.7 million (2021), whereas its average is -$52.9 million.
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Income from Continuing Operations tumbled by 36637.3% in 2024, and later soared by 38962.8% in 2025.
  • Arrowhead Pharmaceuticals' Income from Continuing Operations (Quarter) stood at -$62.9 million in 2021, then soared by 33.5% to -$41.8 million in 2022, then crashed by 223.78% to -$135.4 million in 2023, then fell by 29.43% to -$175.2 million in 2024, then soared by 116.12% to $28.2 million in 2025.
  • Its last three reported values are $28.2 million in Q4 2025, $16.1 million for Q3 2025, and -$178.7 million during Q2 2025.